A clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases, with a pipeline of mono and multispecific antibodies and an initial focus on atopic dermatitis and inflammatory bowel disease.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| $165 M | Jun, 2026 | series-a |
Industries
Frequently Asked Questions
Where is Bionyra Pharma located?
Bionyra Pharma is located in Paris and Boston, France and United States.
What industries does Bionyra Pharma operate in?
Bionyra Pharma operates in the following industries: biopharmaceuticals, biotechnology, healthcare.
How much total funding has Bionyra Pharma raised?
Bionyra Pharma has raised a total of $165,000,000.
Who are the investors in Bionyra Pharma?
The investors in Bionyra Pharma are: Jeito Capital, Sofinnova Partners, Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, Apollo Health Ventures.
What is Bionyra Pharma?
Bionyra Pharma is a clinical-stage biopharmaceutical company that develops next-generation biologics to treat severe immune-mediated inflammatory diseases.
What is the primary focus of Bionyra Pharma's pipeline?
The company focuses on developing mono and multispecific antibodies with half-life extension technology, primarily targeting conditions such as inflammatory bowel disease and atopic dermatitis.
Who leads Bionyra Pharma?
Bionyra Pharma was co-founded by its CEO, Dr. Frédéric Marrache, a former R&D executive at Sanofi with extensive experience in immunology and inflammation.
Is Bionyra Pharma a public company?
No, Bionyra Pharma is a private company. It recently announced an oversubscribed Series A financing round of $165 million.
Where is Bionyra Pharma located?
Bionyra Pharma is based in Paris, France.